TY - JOUR
T1 - Analysis of the efficacy and safety of recombinant tissue plasminogen activator for Chinese patients over 80 years of age with acute ischemic stroke : a pilot study
AU - Yang, Jiandao
AU - Liang, Huazheng
AU - Song, Yanyan
AU - Shen, Lingda
AU - Wang, Shaoshi
PY - 2016
Y1 - 2016
N2 - Recombinant tissue plasminogen activator (rt-PA) remains the only proven therapy for acute ischemic stroke patients who meet the selection criteria for treatment [1-3]. A small number of studies have investigated the efficacy of rt-PA for elderly stroke patients in Japanese and Caucasian populations [4, 5]. According to the American Heart Association/American Stroke Association Guidelines, patients over 80 years of age can be selected for rt-PA thrombolysis [6] and the Third International Stroke Trial found that the benefit of rt-PA did not diminish in patients older than 80 years [7]. However, the Chinese Guidelines for Stroke Management do not recommend rt-PA thrombolysis for these patients, due to the possibility that it increases the risk of intracranial hemorrhage transformation and subsequent nosocomial mortality [8]. In addition, an epidemiological study in Europe showed that >30% of the people included in their study who were >80 years old developed ischemic stroke after rt-PA treatment [5]. In China, there have been no such studies. Therefore, there is a urgent need to confirm the safety and efficacy of rt-PA in these patients [4, 5]. The present study aimed to reveal whether rt-PA could be safely and efficiently used on Chinese patients >80 years old with acute ischemic stroke. To do this, measures of safety and neurological function of these patients after rt-PA thrombolysis were compared with their younger counterparts (60-80 years) who also received rt-PA thrombolysis and patients >80 years old who did not receive rt-PA thrombolysis.
AB - Recombinant tissue plasminogen activator (rt-PA) remains the only proven therapy for acute ischemic stroke patients who meet the selection criteria for treatment [1-3]. A small number of studies have investigated the efficacy of rt-PA for elderly stroke patients in Japanese and Caucasian populations [4, 5]. According to the American Heart Association/American Stroke Association Guidelines, patients over 80 years of age can be selected for rt-PA thrombolysis [6] and the Third International Stroke Trial found that the benefit of rt-PA did not diminish in patients older than 80 years [7]. However, the Chinese Guidelines for Stroke Management do not recommend rt-PA thrombolysis for these patients, due to the possibility that it increases the risk of intracranial hemorrhage transformation and subsequent nosocomial mortality [8]. In addition, an epidemiological study in Europe showed that >30% of the people included in their study who were >80 years old developed ischemic stroke after rt-PA treatment [5]. In China, there have been no such studies. Therefore, there is a urgent need to confirm the safety and efficacy of rt-PA in these patients [4, 5]. The present study aimed to reveal whether rt-PA could be safely and efficiently used on Chinese patients >80 years old with acute ischemic stroke. To do this, measures of safety and neurological function of these patients after rt-PA thrombolysis were compared with their younger counterparts (60-80 years) who also received rt-PA thrombolysis and patients >80 years old who did not receive rt-PA thrombolysis.
KW - Chinese
KW - acute ischemic stroke
KW - cerebrovascular disease
KW - older people
KW - tissue plasminogen activator
UR - http://handle.uws.edu.au:8081/1959.7/uws:36734
U2 - 10.1007/s12264-016-0020-2
DO - 10.1007/s12264-016-0020-2
M3 - Article
SN - 1673-7067
VL - 32
SP - 202
EP - 203
JO - Neuroscience Bulletin
JF - Neuroscience Bulletin
IS - 2
ER -